Geneseeq is an industry leader in next-generation sequencing (NGS) fully committed to the research and clinical translation of NGS genetic sequencing in the field of personalized medicine.
Geneseeq?s world-leading laboratories are accredited by College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA), and have sequenced over 250,000 cancer samples.
Geneseeq currently owns all of Illumina?s sequencing platforms, including MiSeq, NextSeq500, HiSeq4000, HiSeq X10 and NovaSeq 6000.